Objectives-To examine the efficacy of population screening for haemochromatosis by analysing the screening performance of seven intervention trials, and to compare this with the expected performance derived from family studies. Setting-Seven population intervention trials carried out between 1983 and 1995 in Australia, Scandinavia, Iceland, and the United States. Methods-Seven of 23 English language trials identified were suitable for the meta-analysis. Transferrin saturation and serum ferritin measurements derived from family studies were used to predict detection and false positive rates for each trial.
Uncertainty exists within the health care community as to whether population screening for haemochromatosis is warranted. This uncertainty can be traced to at least two sources: (1) traditional medical teaching about the disorder, reinforced by limited personal clinical experience, and (2) an apparently contradictory literature, describing results of population based intervention trials. These two sources of doubt cloud the development of health policy and interfere with strategies that might be designed to gain cooperation and acceptance by physicians and patients. Before rational decision-making about population screening for haemochromatosis can take place, therefore, both of these sources of doubt need to be addressed.
Traditional medical teaching characterises haemochrornatosis as a "rare" disorder. In medical training, haemochrornatosis is usually described in the context of its fully developed clinical manifestations (for example, "bronze diabetes", arthropathy, cardiomyopathy, cirrhosis, hepatocellular cancer). Primary care physicians will only occasionally diagnose such cases, thereby reinforcing what has been taught. In fact, as many as one in 200 white individuals are homozygous for the haemochrornatosis gene. The speculation that many such homozygous individuals may not develop clinical manifestations gains some validity from family studies, where a proportion of homozygous relatives of clinically diagnosed individuals are symptom-free. However, this does not explain the gap between predicted and actual diagnoses in clinical practice. One explanation is that many cases with clinical manifestations are not being correctly diagnosed. An alternative speculation is that individuals homozygous for haemochrornatosis in the general population are less likely to develop clinical manifestations than family members of clinically diagnosed index cases, possibly due to genetic heterogeneity (different mutations) or variable expression. Population based intervention trials ought to provide data to help resolve these issues.
Twenty three intervention trials have been published in English.':" Some are too small to provide reliable estimates of either homozygote frequency or frequency of clinical manifestations. Others focus on screening individuals who are not representative of the general population, such as hospitalised patients, diabetics, or blood donors. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Blood donors with the homozygous genotype, by being phlebotomised, are actually receiving treatment for their condition, so it is not surprising that clinical manifestations are less frequent. I 4-18 Intervention trials have used differing cut off levels for the screening tests and often do not account for subjects who fail to complete the diagnostic studies, or subjects homozygous for haemochrornatosis whose measurements fall below the screening cut off level. Taking these considerations into account, we analysed the Laboratory standards for transferrin saturation and serum ferritin measurements are the same, irrespective of time and location of trial. 2 Distributions of transferrin saturation and serum ferritin values in homozygous, heterozygous, and unaffected populations are equivalent to those described in the preceding paper." 3
Other disorders associated with positive screening results (e.g, sideroblastic anaemia or multiple transfusions) have been identified and the individuals removed from consideration. 4 Testing second (or third) samples reduces the screen positive rate by 60% at transferrin saturation cut off levels below 55, and by 40% for cut off levels at or above 55 (these estimates were derived from data available in a subset of the studies), 5
Testing second samples reduces the screen positive rate by 60% at serum ferritin cut off levels below 200 !J.!!I1, and by 40% for cut off levels at or above 200 ug/l (no trial contained data that allowed this reclassification rate to be calculated). 6 Individuals lost to follow up are not different from those completing follow up studies.
intervention trials collectively to determine how closely their findings on homozygote frequency and frequency of clinical manifestations align with expectations based on our analysis of family studies."
Methods

CRITERIA FOR INCLUDING AND EXCLUDING
TRlALS FROM THE ANALYSIS Of the 23 published population trials identified, seven ' 7 employed some combination of transferrin saturation and serum ferritin measurements for screening purposes, and provided diagnostic studies for individuals with positive screening results. One trial" was excluded, because it contained duplicate data. I Trials were also excluded if some other screening test (for example, serum iron) was used,":" if diagnostic testing was not routinely available for individuals with positive screening results," " or if the screened population consisted largely of blood donors":" or was not truly population based. [19] [20] [21] [22] [23] 
STATISTICAL ANALYSES
Analyses were performed using the BMDp25 or True Epistat" statistical packages. Confidence intervals of proportions were derived from the binomial distribution. The weighted consensus estimates and 95% confidence intervals were determined using the DerSimonian and Laird method." Distributions of transferrin saturation and serum ferritin were assumed to be bivariate Gaussian, with one exception." Table  1 lists the assumptions necessary for analysing the population screening trials. The first and second allow all of the trials to be analysed against a single set of analyte distributions."
The fourth and fifth enable the impact of repeat testing to be estimated. Since none of the trials provided complete test results for individuals who dropped out, assumption six makes it possible to adjust the homozygote prevalence for these "lost to follow up" individuals. Table 2 shows the seven population screening trials, carried out between 1983 and 1995 in Australia, Scandinavia, Iceland, and the United States, that satisfied the criteria for inclusion in this analysis. A total of 18 396 men and 12 254 women were included. Table 3 lists the criteria used to define individuals at high risk for the homozygous haemochromatosis genotype (numbers assigned to the trials in table 2 correspond to those in subsequent tables and text). The trials are arranged in ascending order, according to the transferrin saturation cut off level used for defining a positive result in the initial serum sample. In six of the seven intervention protocols, a second serum sample was requested for all individuals with positive initial tests; one of these required a third sample. One trial relied solely on measurements from the initial sample.
Results
STUDY SUBJECTS AND SCREENING CRITERIA FOR THE INTERVENTION TRlALS
MODELLING THE DISTRIBUTIONS OF TRANSFERRIN SATURATION AND SERUM FERRITIN
To analyse homozygote frequency and overall screening performance for the intervention trials, we first established reference distributions for transferrin saturation and serum ferritin measurements for each of the genotypes. Figure 1 shows those measurements in a hypothetical group of 5000 men (fig lA) and 5000 women ( fig 1B) with known haemochromatosis genotypes. The measurements displayed are derived from previously calculated population parameters (means, standard deviations, and correlation coefficients). 24 The predicted positive rate using these cut off levels is 3.6% (the total number of observations above and to the right of the thick lines divided by 5000). As a second example, fig IB uses the screening criteria from trial 1 to show the expected screening performance in women.' In this protocol, the initial criterion for defining high risk individuals is a transferrin saturation value of~45 (thin vertical line); the predicted initial positive rate is 11.3%. In testing a second sample, the screening cut off level is again a transferrin saturation value of~45, but also a serum ferritin value of~150 ug/l (thick horizontal line). Although the transferrin saturation cut off levels for the first and second samples are the same (~45), the net effect (shown in the figure) is roughly equivalent to setting a higher cut off level on the initial sample (~50) and not retesting. This phenomenon, known as regression to the mean, is well understood." The thick vertical line drawn at a transferrin saturation of 50 represents the predicted impact of repeat testing; the predicted revised positive rate is 0.8% (the total number of observations in the upper right quadrant divided by 5000). Correlations between first and second sample measurements for the three genotypes have never been published, making it necessary to estimate the impact of repeat testing by using the observed differences between the initial and revised positive rates.' 5-7 " A 40% reduction in the positive rate (table 1) approximating the effect of repeat testing can be achieved by moving the transferrin saturation cut off level from 45 to 50. Reduction in the detection rate is likely to be slightly overestimated, because results from repeat tests in homozygous individuals would tend to be higher, rather than lower.
In table 4, this approach is applied to all seven trials to predict initial and revised positive rates, and to compare them with reported rates. Predicted and reported rates are in reasonable agreement, except for the initial positive rate in trial 1. 6, and 7) , screen positive individuals who did not complete diagnostic testing were not considered when prevalence was calculated. Our analysis considers both factors when estimating the adjusted prevalence. Table 5 shows the reported and adjusted prevalence estimates for the homozygous genotype in the seven trials. The prevalences reported are based on the number of individuals diagnosed as being homozygous for haemochromatosis, divided by the total number screened. The adjusted prevalence rates in table 5 (34 per 10 000 men (95% confidence interval 17 to 84) and 40 per 10 000 women (95% confidence interval 19 to 77) respectively) are considerably higher than originally reported, and are much closer to the prevalence estimate of 53 per 10 000 derived from family studies.
CALCULATION OF THE FREQUENCY OF CLINICAL
MANIFESTATIONS
Collectively, the seven trials initially identified about 1.6% of the 18 396 men and 0.8% of the 12 254 women as screen positive. Seventy one subjects declined further testing. After follow up screening, 65 men and 10 women remained screen positive and were offered liver biopsy (and other diagnostic tests in some cases); 63 men and nine women accepted. Estimates of total body iron stores (quantitative phlebotomy) were available for 20 men and five women; quantitative liver iron was available for 45 men and seven women. Table 6 shows clinical manifestations identified in the 28 men and nine women diagnosed as being homozygous. Overall, 50% of men and 44% of women displayed at least one clinical manifestation (including hepatic fibrosis). The rate of manifestations in women is consistent with the 41 % expected from family studies.'4 For men, the percentage is lower than the predicted 67%, but the difference is not significant (X' = 2.7, P = 0.1). Screening and diagnostic test results and a list of signs and symptoms for the 37 individuals are contained in the appendix.
Discussion
Transferrin saturation and serum ferritin measurements from individuals with known haemochromatosis genotypes allow us to construct a model for analysing screening performance in the intervention trials. '4 In all but one trial, estimated and reported screen positive rates agreed well, validating the model and providing indirect evidence that laboratory measurements were reasonably well standardised in the various trial locations. The model also allows detection rates to be estimated for the widely varying screening criteria used in the trials, resulting in a more accurate estimate of the prevalence of the homozygous genotype.
Adjusting the reported prevalences from the trials to account for homozygous individuals who were screen negative, and for screen positive individuals who did not receive diagnostic * The initial positive rates were not reported seperately for men and women.
*A complete list of signs and symptoms can be found in the appendix. Table 4 A comparison of the reported versus predicted screen positive rates in the seven studies In actuality, the spectrum of morbidity and mortality is somewhere between these extremes. The rate of clinical manifestations among women in the intervention trials is consistent with expectations; among men the rate is lower than expected, but the difference does not reach statistical significance. Although this may be due to chance, it is also possible that some heterozygotes with relatively high iron stores were incorrectly classified as homozygotes. Alternatively, the rate of clinical manifestations in family studies might be overestimated because of biases of ascertainment. For example, family members with symptomatology may be more likely to agree to evaluation, or family members of symptomatic index cases may be more aware of, and therefore more likely to report, non-specific symptoms (for example, abdominal or joint pain).
The feasibility of population screening also depends on the availability of reliable and safe screening and diagnostic tests. Evidence from both family and population studies documents the efficacy of transferrin saturation and serum ferritin measurements, and allows judgments to be made as to an appropriate balance between detection and false positive rates."-31 Quantification of hepatic iron (liver biopsy) is a highly reliable diagnostic test." However, such measurements may be less definitive when the iron burden is less, making it difficult to distinguish between heterozygous and young homozygous individuals." 32" Some studies suggest that the hepatic iron index (the ratio of the hepatic iron concentration to age) may be helpful in such cases. However, it has not yet been demonstrated to be useful as an adjunct to population screening." 3. In addition, although the complication rate is low, liver biopsy may not always be acceptable to asymptomatic individuals." Quantitative phlebotomy, a less invasive method, provides a measurement of total body iron stores with reasonable diagnostic reliability, but lacks the information on prognosis provided by liver histology (for example, fibrosis, cirrhosis). 32 36 37 Aggressive phlebotomy is the accepted treatment for removing excess iron," 38 and is simple, effective (especially if begun before symptoms appear), and widely (but not universally) available. Because of a blood banking policy that prohibits any person diagnosed with haemochromatosis from acting as a blood donor, phlebotomy must be performed as a medical procedure, even in asymptomatic individuals, and at significant cost. Some asymptomatic individuals who are told that they are homozygous for haemochromatosis may be reluctant to enter a phlebotomy treatment protocol. These uncertainties lead to a number of other concerns, such as "labelling" of asymptomatic or unaffected individuals, appropriate testing, yields a combined estimate of 34 and 40 per 10 000 for men and women respectively. These are somewhat lower than the 53 per 10 000 estimated from family studies." This is mainly due to trial number 7 which, although very large, reported an extremely low prevalence. No explanation for this discrepancy is apparent. If trial 7 is excluded, the prevalence rates of 50 (95% confidence interval 17 to 84) and 62 (95% confidence interval 27 to 97) per 10 000 for men and women in the remaining trials agree even more closely with expectations. In considering population screening as a strategy for reducing morbidity and/or mortality for any medical condition, the spectrum of morbidity and mortality associated with the condition must be documented. If the homozygous genotype were only rarely associated * In all studies, adjusting prevalence involves taking into account the estimated number of homozygous individuals with negative screening results. In addition, studies 1, 6 and 7 were adjusted for individuals lost during the follow up studies. tOverall prevalence is estimated using a published methodology.27 If trial 7 were removed, the overall prevalences would change to 26, SO, 25 and 62 per 10 DOD from left to right, respectively. Table 6 Clinical manifestations in 28 men and nine women diagnosed as being homozygous for haemochromatosis diagnostic and treatment policies, insurance issues, and management of other family members.
Current knowledge about haemochromatosis, including experience gained from population trials, supports the efficacy of transferrin saturation as a screening test, but does not clarify how best to proceed with regard to programmatic issues. If population screening is to be implemented, then insights gained from the field of prenatal screening might prove useful in shaping policy. Appropriate cut off levels for the screening trials would need to be considered, while keeping the screen positive rate as low as possible. Educating physicians and other health personnel would be a priority. Patients would need to be aware of the screening process and agree to be tested. Making them aware of testing only after a positive screening result could create unnecessary anxiety and resistance to follow up testing. Recommendations need to be developed as to how haemochromatosis should be described to individuals diagnosed as having the disorder, including informational materials for discussion and counselling. The frequency and type of follow up assessment needs to be standardised to maximise benefit to the patient. Appropriate recommendations for other family members need to be considered.
A recent article described the identification of a candidate haemochromatosis gene, and reported that two missense mutations accounted for 88% of 178 patients tested with haemochromatosis (149 homozygotes, eight compound heterozygotes)." This raises the possibility of a DNA based screening test, expected to have a low false positive rate, which could detect most individuals homozygous for haemochromatosis. The genotype-phenotype relationship for these mutations is not yet known, however, so the proportion of the homozygotes identified who are expected to develop symptoms remains unclear. A further, and as yet unresolved, consideration is the relative cost/efficacy of a DNA based test versus the traditional screening test. Regardless of the screening method selected, incorporating all of the programmatic components discussed above into future pilot studies will be important.
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